NCT Number: NCT05568550
Phase:
Trial Summary: This trial will evaluate whether the immune-sensitizing effects of immunotherapy (Pembrolizumab) and radiation with or without a PARP-inhibitor (Olaparib) will increase the effects of immunotherapy in – clinicaltrials.gov for more information and location
Clinicaltrials.gov
Trial Sponsor(s): Zin W Myint
Acronym:
Pembro With Radiation With or Without Olaparib
— PHENTrials.com Increasing Participation in Prostate Cancer Clinical Trials to Save Lives